Glucocorticoid-induced osteoporosis: Mechanisms, management, and future perspectives

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 59-70

  Seibel, Markus J ^a   Cooper, Mark S ^a   Zhou, Hong ^a  

^a ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLONY STIMULATING FACTOR 1; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IBANDRONIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BIOSYNTHESIS; BONE DEVELOPMENT; BONE METABOLISM; CATABOLISM; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; HYPOGONADISM; IMMUNOMODULATION; MESENCHYME CELL; MINERAL METABOLISM; NONHUMAN; OBESITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; BONE DENSITY; CHEMICALLY INDUCED; DISEASE MANAGEMENT; DRUG EFFECTS; FORECASTING; FRACTURES, BONE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE DENSITY; DISEASE MANAGEMENT; FORECASTING; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 84882715088     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70045-7     Document Type: Review

References (107)

1. Hench PS, Kendall EC, Slocumb C, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949, 24:181-197.
2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996, 313:344-346.
3. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105-111.
4. Diez-Perez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. Bone 2011, 49:493-498. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
5. Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011, 63:1-9.
6. Henderson NK, Sambrook PN Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr Opin Rheumatol 1996, 8:365-369.
7. Schakman O, Gilson H, Thissen JP Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197:1-10.
8. Weinstein RS Glucocorticoid-induced osteonecrosis. Endocrine 2012, 41:183-190.
9. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387.
10. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
11. Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M, Tattersfield AE Morbidity from asthma in relation to regular treatment: a community based study. Thorax 1999, 54:296-300.
12. Walsh LJ, Lewis SA, Wong CA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002, 166:691-695.
13. van Staa TP, Leufkens HG, Cooper C The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
14. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383-1389.
15. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
16. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485-2494.
17. Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 2012, 27:2039-2046.
18. Cooper MS, Zhou H, Seibel MJ Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets?. J Bone Miner Res 2012, 27:2238-2241.
19. Stewart PM, Krozowski ZS 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 1999, 57:249-324.
20. Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001, 16:1037-1044.
21. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010, 11:517-531.
22. Sher LB, Harrison JR, Adams DJ, Kream BE Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 2006, 79:118-125.
23. Sher LB, Woitge HW, Adams DJ, et al. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 2004, 145:922-929.
24. Zhou H, Mak W, Kalak R, et al. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 2009, 136:427-436.
25. Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 2008, 283:1936-1945.
26. Kalak R, Zhou H, Street J, et al. Endogenous glucocorticoid signaling in osteoblasts is necessary to maintain normal bone structure in mice. Bone 2009, 45:61-67.
27. Yang M, Trettel LB, Adams DJ, Harrison JR, Canalis E, Kream BE Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation. Bone 2010, 47:573-582.
28. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI Characterization of cells with osteogenic potential from human marrow. Bone 1992, 13:81-88.
29. Herbertson A, Aubin JE Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures. J Bone Miner Res 1995, 10:285-294.
30. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009, 85:538-545.
31. Li A, Hardy R, Stoner S, Tuckermann J, Seibel MJ, Zhou H Deletion of mesenchymal glucocorticoid receptor attenuates embryonic lung development and abdominal wall closure. PLoS One 2013, 8:e63578.
32. Day TF, Guo X, Garrett-Beal L, Yang Y Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.
33. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 2000, 27:375-381.
34. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010, 9:147-161.
35. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002, 17:979-986.
36. Justesen J, Mosekilde L, Holmes M, et al. Mice deficient in 11beta-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 2004, 145:1916-1925.
37. Cooper MS, Syddall HE, Fall CH, et al. Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. Clin Endocrinol (Oxf) 2005, 62:692-697.
38. Hwang JY, Lee SH, Kim GS, et al. HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone 2009, 45:1098-1103.
39. Tiganescu A, Tahrani AA, Morgan SA, et al. 11beta-hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest 2013, published online June 3. 10.1172/JCI64162.
40. Baschant U, Frappart L, Rauchhaus U, et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci USA 2011, 108:19317-19322.
41. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
42. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
43. Liu Y, Porta A, Peng X, et al. Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 2004, 19:479-490.
44. Shi XM, Blair HC, Yang X, McDonald JM, Cao X Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 2000, 76:518-527.
45. Carcamo-Orive I, Gaztelumendi A, Delgado J, et al. Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J Bone Miner Res 2010, 25:2115-2125.
46. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 2012, 97:E1953-E1957.
47. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008, 149:1793-1801.
48. Prummel MF, Wiersinga WM, Oosting H, Endert E The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1. J Endocrinol Invest 1996, 19:620-623.
49. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
50. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
51. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
52. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008, 103:335-345.
53. Rubin J, Biskobing DM, Jadhav L, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 1998, 139:1006-1012.
54. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592-5599.
55. Cooper MS, Blumsohn A, Goddard PE, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 2003, 88:3874-3877.
56. Kaur K, Hardy R, Ahasan MM, et al. Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis 2010, 69:1185-1190.
57. Coutinho AE, Gray M, Brownstein DG, et al. 11beta-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 2012, 153:234-240.
58. Cooper MS, Kriel H, Sayers A, et al. Can 11beta-hydroxysteroid dehydrogenase activity predict the sensitivity of bone to therapeutic glucocorticoids in inflammatory bowel disease?. Calcif Tissue Int 2011, 89:246-251.
59. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
60. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest 2012, 122:4172-4189.
61. Perez AV, Picotto G, Carpentieri AR, Rivoira MA, Peralta Lopez ME, Tolosa de Talamoni NG Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway. Digestion 2008, 77:22-34.
62. Ritz E, Kreusser W, Rambausek M Effects of glucocorticoids on calcium and phosphate excretion. Adv Exp Med Biol 1984, 171:381-397.
63. Chrousos GP, Torpy DJ, Gold PW Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998, 129:229-240.
64. Pereira RM, Freire de Carvalho J Glucocorticoid-induced myopathy. Joint Bone Spine 2011, 78:41-44.
65. van der Goes MC, Jacobs JW, Jurgens MS, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?. Osteoporos Int 2013, 24:1429-1436.
66. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008, 67:823-828.
67. Goemaere S, Liberman UA, Adachi JD, et al. Incidence of nonvertebral fractures in relation to time on treatment and bone density in glucocorticoid-treated patients: a retrospective approach. J Clin Rheumatol 2003, 9:170-175.
68. Tatsuno I, Sugiyama T, Suzuki S, et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009, 94:1671-1677.
69. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48:3224-3229.
70. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899.
71. Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. Osteoporos Int 1999, 9:206-213. European Vertebral Osteoporosis Study Group.
72. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005, 23:105-109.
73. Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012, 23:2257-2276.
74. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010, 62:1515-1526.
75. Russcher H, Smit P, van den Akker EL, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab 2005, 90:5804-5810.
76. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009, 2. CD007146.
77. Lane NE, Lukert B The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998, 27:465-483.
78. Amin S, LaValley MP, Simms RW, Felson DT The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999, 42:1740-1751.
79. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:961-968.
80. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002, 109:1041-1048.
81. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
82. Weinstein RS, Nicholas RW, Manolagas SC Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
83. Dunstan CR, Felsenberg D, Seibel MJ Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007, 4:42-55.
84. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
85. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
86. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370:657-666.
87. Sambrook PN Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000, 15:1645-1649.
88. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993, 328:1747-1752.
89. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003, 18:919-924.
90. Marcus R, Wong M, Heath H, Stock JL Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002, 23:16-37.
91. Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012, 50:289-295.
92. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-299. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
93. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009, 24:1335-1344.
94. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003, 14:801-807.
95. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
96. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010, 151:2641-2649.
97. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
98. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
99. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
100. Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010, 37:141-148.
101. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998, 83:801-806.
102. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
103. Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011, 70:778-784.
104. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010, 69:872-875.
105. Tchen CR, Martins JR, Paktiawal N, Perelli R, Saklatvala J, Clark AR Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J Biol Chem 2010, 285:2642-2652.
106. Thiele S, Ziegler N, Tsourdi E, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012, 27:2242-2250.
107. Ferris HA, Kahn CR New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest 2012, 122:3854-3857.